Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Alpha Tau Medical Ltd (DRTS)
Alpha Tau Medical Ltd (DRTS) Actualités

Alpha Tau Medical Ltd (DRTS)

12,40

-1,18

( -8,66% )

Mis à jour : 16:06:20

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

- First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in...

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients...

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

- Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s...

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive...

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local...

Alpha Tau to Participate in May Investor Conferences

JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete...

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the...

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the...

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute

First patient ever treated with Alpha DaRT for pancreatic cancer in Italy, under a clinical study conducted at...

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

- Abstract from trial evaluating Alpha DaRT® in combination with pembrolizumab in elderly patients with locally...

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

- 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human...

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

- Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world’s largest...

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

- IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer...

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Alpha Tau Medical

Eqty Lkd Nts 01/03/27

4Front Ventures

AdvisorShares FolioBeyon...

Fidelity Disruptive Fina...

First Savings Financial

Sixty Six Oilfield Servi... (ID)

APM Human Services

Agf Enhanced Us Equity I...

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

ADVFN

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.